Compare Stocks

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EPIX ESSA Pharma	$6.32 -6.0%	$8.68	$2.56 ▼ $11.67	$279.60M	1.62	138,056 shs	102,387 shs
MORF Morphic	$27.99 +1.7%	$34.38	$19.34 ▼ $63.08	$1.40B	1.42	505,780 shs	383,671 shs
PLXP PLx Pharma		$0.00	$0.02 ▼ $0.04	$603K	3.79	12.96 million shs	3,000 shs
VVUS VIVUS		$0.37	$0.44 ▼ $4.75	$7.33M	-0.84	1.44 million shs	2.03 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EPIX ESSA Pharma	-4.95%	-18.55%	-27.74%	-23.46%	+136.62%
MORF Morphic	-1.29%	-9.27%	-18.85%	+3.27%	-38.48%
PLXP PLx Pharma	0.00%	0.00%	0.00%	0.00%	-99.29%
VVUS VIVUS	0.00%	0.00%	0.00%	0.00%	0.00%

SHOCKING Crypto Leak… (Ad)

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EPIX ESSA Pharma	2.8541 of 5 stars	3.5	4.0	0.0	0.0	2.8	3.3	0.0
MORF Morphic	3.4829 of 5 stars	3.3	1.0	0.0	4.8	1.3	3.3	0.0
PLXP PLx Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VVUS VIVUS	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EPIX ESSA Pharma	3.00	Buy	$16.50	161.08% Upside
MORF Morphic	2.67	Moderate Buy	$61.00	117.93% Upside
PLXP PLx Pharma	N/A	N/A	N/A	N/A
VVUS VIVUS	N/A	N/A	N/A	N/A

Current Analyst Ratings

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	$3.30 per share	N/A
MORF Morphic	$520K	2,693.50	N/A	N/A	$14.01 per share	2.00
PLXP PLx Pharma	$4.54M	0.00	N/A	N/A	$1.30 per share	0.00
VVUS VIVUS	$69.76M	0.00	N/A	N/A	($6.50) per share	0.00

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EPIX ESSA Pharma	-$26.58M	-$0.59	N/A	N/A	N/A	N/A	-17.41%	-17.04%	5/14/2024 (Estimated)
MORF Morphic	-$152.10M	-$3.49	N/A	N/A	N/A	N/A	-23.62%	-22.90%	4/23/2024 (Estimated)
PLXP PLx Pharma	-$46.13M	-$1.85	N/A	N/A	N/A	-606.91%	-291.11%	-119.43%	N/A
VVUS VIVUS	-$31.50M	-$2.96	N/A	N/A	N/A	-39.28%	N/A	-12.18%	N/A

Latest VVUS, EPIX, MORF, and PLXP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
2/22/2024	Q4 2023	MORF Morphic	-$0.89	-$0.94	-$0.05	-$0.94	N/A	N/A
2/13/2024	12/31/2023	EPIX ESSA Pharma	-$0.17	-$0.14	+$0.03	-$0.14	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	N/A
MORF Morphic	N/A	N/A	N/A	N/A	N/A
PLXP PLx Pharma	N/A	N/A	N/A	N/A	N/A
VVUS VIVUS	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EPIX ESSA Pharma	N/A	40.74	40.74
MORF Morphic	N/A	28.94	28.94
PLXP PLx Pharma	N/A	4.79	4.28
VVUS VIVUS	N/A	0.43	0.28

Ownership

Institutional Ownership

Company	Institutional Ownership
EPIX ESSA Pharma	75.12%
MORF Morphic	94.25%
PLXP PLx Pharma	21.19%
VVUS VIVUS	7.32%

Insider Ownership

Company	Insider Ownership
EPIX ESSA Pharma	14.70%
MORF Morphic	28.10%
PLXP PLx Pharma	8.95%
VVUS VIVUS	12.00%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
EPIX ESSA Pharma	50	44.24 million	37.74 million	Optionable
MORF Morphic	121	50.04 million	35.98 million	Optionable
PLXP PLx Pharma	16	29.14 million	26.53 million	Not Optionable
VVUS VIVUS	57	17.87 million	N/A	Optionable

VVUS, EPIX, MORF, and PLXP Headlines

Source	Headline
	VIVUS Provides Update on Pipeline and Program Milestones markets.businessinsider.com - January 8 at 10:04 AM
	Shark research group to build new global headquarters in Jacksonville with help from state funding actionnewsjax.com - June 26 at 9:16 AM
	Metaview announces Answers, the world's first conversational AI for the interview process it.tmcnet.com - May 25 at 11:10 AM
	Pancrelipase (CAS 53608-75-6) Market 2023 \| Industry Growth ... - StreetBuzz news.google.com - May 12 at 2:58 AM
	Exploring Huge Demand of Peripherally Acting Anti-Obesity Drug ... - Digital Journal news.google.com - May 12 at 2:58 AM
	Extensive Growth Opportunities to be Witnessed by Prescription Weight-Loss Pills Market 2023 Analysis of Risin - openPR news.google.com - May 11 at 8:54 AM
	Erectile Dysfunction Drugs Market to Register High Demand Rate by ... - Cottonwood Holladay Journal news.google.com - May 11 at 8:54 AM
	Milestone Pharmaceuticals Reports First Quarter 2023 Financial ... - PR Newswire news.google.com - May 11 at 8:54 AM
	Anti-obesity Therapeutics Market to Witness the Highest Growth ... - Cottonwood Holladay Journal news.google.com - May 11 at 3:54 AM
	Anti Obesity Drugs Market Future Industry Scope for New ... - Digital Journal news.google.com - May 11 at 3:54 AM
	This Crazy Six-Wheel Hatchback by Briggs & Stratton Was One of ... - autoevolution news.google.com - May 10 at 12:51 PM
	Prostatic Artery Embolization Market Current and Upcoming Projects ... - Digital Journal news.google.com - May 9 at 6:48 AM
	This 1899 Porsche Pioneered Rivian's Quad-Motor Drive, Ram ... - MotorBiscuit news.google.com - May 7 at 8:20 PM
	Porsche Pioneered the Range-Extended EV 100+ Years Before ... - MotorBiscuit news.google.com - May 6 at 3:22 PM
	Increasing Opportunities In Peripherally Acting Anti-Obesity Drug Market Latest Trends, Technological Advancem - openPR news.google.com - May 5 at 1:45 PM
	Nonalcoholic Steatohepatitis Treatment Market Outlook Growths ... - Digital Journal news.google.com - May 5 at 7:44 AM
	A Big Fat Problem: Will children in the UK be given weight-loss injections? - Firstpost news.google.com - May 2 at 10:24 AM
	Intraoperative Ultrasound Market Latest Trends, Techniques and Applications\|2023-2030 - openPR news.google.com - April 28 at 9:38 AM
	Build Your Own Case Study \| Obesity: Treating the Whole Patient - Healio news.google.com - April 27 at 8:14 PM
	Bladder Cancer Market Demand in Various industries and Significant for Various Regions\|2023-2030 - openPR news.google.com - April 27 at 3:10 PM
	Pediatric Obesity Management Market is projected to grow with a 4 ... - Future Market Insights news.google.com - April 27 at 10:10 AM
	Global Erectile Dysfunction Drugs Market Analysis by Recent Trends, Development, Regional Growth Overview and - openPR news.google.com - April 26 at 7:33 AM
	Non-Alcoholic Steatohepatitis (NASH) Market Analysis, Trends, Growth, Research And Forecast 2032 - openPR news.google.com - April 25 at 2:02 AM
	What to Know About Obesity and Bone Health - Health Central news.google.com - April 24 at 4:02 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

ESSA Pharma

NASDAQ:EPIX

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Morphic

NASDAQ:MORF

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

PLx Pharma

NASDAQ:PLXP

PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. It offers PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Sparta, NJ.

VIVUS

NASDAQ:VVUS

VIVUS, Inc. engages in the development and commercialization of novel therapeutic products. The firm's products are indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and is headquartered in Campbell, CA.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial